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Fellow geneticists, old friends and new, I am truly
honored to be your President in this first year of the new
millennium, and a year that marks the 50th annual meet-
ing of the American Society of Human Genetics. A pres-
idential address to the Society is a difficult task. Some
of your past presidents have reflected on topics that were
important at the time; others have reviewed a decade of
achievement or made predictions about the coming dec-
ade. Those who have served in a year that marks a So-
ciety anniversary have used the occasion to reflect on
the Society and its role. None, however, have had the
daunting task of standing before the Society on the 50th
anniversary of the annual meeting, in the first year of a
new decade, a new century, and a new millennium, in
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a year that might well be called “The Year of Our
Genome.”
What I want to do today is to look back over the last
century and touch on some of the highlights, then spend
a few minutes on the biggest event of the century—the
Human Genome Project. I will then look at the future
of human genetics and will end with some thoughts on
the role of the Society in the new millennium. These
thoughts will reflect discussions held at a retreat of the
ASHG Board of Directors in the spring of 2000.
Looking Back
In reflecting on the past, one thing struck me, and that
is the enormous amount of knowledge that has been
forthcoming in a time frame that is miniscule in com-
parison with the time of human existence, or even com-
pared with the span of the last millennium. Indeed, the
principle of inheritance did not even emerge until the
start of the 20th century, and it was not until 1915 that
the architecture of the genetic material was first de-
scribed. If we date the definitive elucidation of the phys-
ical basis of heredity to Morgan’s 1926 Theory of the
Gene, it tells us that, for the first 925 years of the last
millennium, the world was ignorant of this fundamental
principle.
The second quarter of the century was not great for
human genetics. Quoting Dunn in his 1961 presidential
address (Dunn 1962), “progress in human genetics
seemed to have been impeded less by a lack of means
than by a lack of clear scientific goal, and this at a time
when the major problems of genetics were taking a clear
form.”While studies of fruit flies were revealing the prin-
ciples of gene transmission, conservation, and evolution,
“most observations on human heredity were not oriented
in any clear way toward such problems. Matters of
greater moment seemed to be the inheritance of ‘insanity’
and ‘feeblemindedness’ and other vaguely definedmental
ills … pursued for immediate social ends.”
As human genetics emerged from the eugenics period,
the role of genes in disease was poorly understood, as
revealed by H. J. Muller in his 1950 presidential address
(Muller 1950). Quoting an editorial in the Journal of
the American Medical Association, he noted that “until
recently the prevailing view has been that mutation as
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a direct cause of disease is extremely rare and of little
practical significance. Since observational data are lim-
ited to relatively few generations and since human cross-
breeding experiments may not be performed, we shall
never be able to demonstrate with certainty that a he-
reditary human disease arises from mutation.” This was
1947, not the Middle Ages.
The third quarter of the 20th century began a true
golden age of genetics. Following the discovery of DNA
as the genetic material in 1948 and the description of
its structure in 1953, rapid progress ensued to determine
the genetic code and the intermediate role of RNA in
the process of manufacturing protein. The rapid gains
were all achieved in simple organisms, including phage
and bacteria—the age of human molecular genetics still
two decades away.
For human genetics, the third quarter of the century
was the time when biochemical genetics, clinical genet-
ics, and cytogenetics began to flourish. Building on the
work of the pioneers who studied blood groups and
clotting factors, new technologies such as chromatog-
raphy and gel electrophoresis launched the discipline of
biochemical genetics. Victor McKusick, in his 1975
presidential address, identifies 1959 as the origin of both
clinical genetics and cytogenetics (McKusick 1975). The
discovery in 1960 of an extra chromosome 21 in Down
syndrome will stand as one of the landmark discoveries
of all time, and it was the driving force behind the later
development of prenatal diagnosis for genetic disorders.
The discovery of the sex-chromosome anomalies
XXX, XXY, and XYY presented a special problem for
researchers who wished to determine the true phenotype
without biasing the family’s treatment of the affected
individual. The controversy over newborn screening
programs to identify and study such individuals was
politically intense and became the subject of John Ham-
erton’s presidential address in 1976 (Hamerton 1976).
The last quarter of the century can truly be called the
era of human molecular genetics—beginning with re-
combinant DNA technology that had surfaced at Stan-
ford in 1976 and then gone underground, both figu-
ratively and literally, for 2 years to assess the safety of
recombinant molecules. Early landmarks included Y.W.
Kan’s demonstration that a polymorphism in the b-glo-
bin gene could be used to predict sickle cell disease in
utero (Kan et al. 1976) and the 1980 paper by Ray
White, David Botstein, and colleagues outlining how
RFLPs could be used as genetic markers to track and
map disease genes in families (Botstein et al. 1980).
Many of the early discoveries in human molecular
genetics were reported at meetings of the ASHG, mak-
ing this an exciting time to be a member of the Society.
I will always remember the 1984 meeting in Toronto
(then my home) when Jane Gitschier, then a postdoc-
toral fellow at Genentech, reported the cloning of the
factor VIII gene and stunned the audience with the enor-
mity of the effort and the sheer size of the gene—180
kb. Of course, to someone who has now spent more
than a decade working with the 2,500-kb dystrophin
gene, 180 kb seems downright civilized.
Prior to 1985, it was not possible to predict the im-
pact that new technology would have on the cloning of
human-disease genes by positional cloning. One of the
first was the Duchenne muscular dystrophy gene (the
DMD gene), cloned by isolating DNA from band p21
of the X chromosome. I had the good fortune to be
intimately involved in the identification of the DMD
gene (Ray et al. 1985) and, along the way, made lasting
friendships with my three erstwhile competitors and
sometime collaborators: Lou Kunkel, Kay Davies, and
Ed Southern.
While speaking about the DMD gene–cloning effort,
I want to acknowledge three colleagues who were crit-
ical to the gene cloning and to my own career devel-
opment. The first is Christine Verellen, a friend and
colleague from Belgium, who demonstrated that an X:
21 translocation in a young Belgian girl with muscular
dystrophy caused the disease by breaking through the
gene and inactivating the normal X chromosome (Ver-
ellen-Dumoulin et al. 1984). This young girl’s DNA
became the substrate of our gene-cloning effort. The
second is Peter Ray, a molecular biologist who joined
the cloning project shortly after it started and became
a valuable collaborator and friend for the next 12 years.
The third is Roy Schmickel, former head of the De-
partment of Human Genetics here at the University of
Pennsylvania, who provided critical DNA probes and
assisted us in cloning the X:21 translocation junction.
His tragic accidental death robbed the human genetics
community and the city of Philadelphia of a great sci-
entific leader. This address is dedicated to his memory.
I couldn’t leave the 1980s without saying a fewwords
about cystic fibrosis (CF). In 1983, a young member of
our faculty consulted me about using RFLPs to map the
CF gene. My advice was to forget it, as I perceived it
as a high-risk project and a potential drag on his career.
Little did I know then that Lap-Chee Tsui would map
the gene within 2 years and clone it 4 years later. Clon-
ing the CF gene by Lap-Chee’s laboratory in collabo-
ration with the groups of Jack Riordan and Francis
Collins was a true landmark. The set of three papers in
Science (Kerem et al. 1989; Riordan et al. 1989; Rom-
mens et al. 1989), which should be on the required
reading list of every graduate student in human genetics,
laid it all out, demonstrated that it was possible, and
opened the floodgates for a decade of positional cloning.
This thumbnail sketch brings us to 1989, the date
most often attributed to the start of the HumanGenome
Project. The driving force was the realization that the
only way to identify genes involved in complex disease
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was to develop a catalogue of all the human genes, a
map of their chromosomal location, and a sequence of
their nucleotides, to allow prediction of their function.
The Human Genome Project
Those who entered the field of human genetics after
1990 might think that the Human Genome Project
(HGP) was widely supported in the scientific community.
In fact, it was launched with considerable controversy.
Many scientists feared that it would drain precious re-
sources from “legitimate” science and that the emphasis
on “human” in the HGP was misguided. Others thought
it simply could not be done. Indeed, I recall a Cold Spring
Harbor meeting in 1986 at which Wally Gilbert filled
the whiteboard with calculations and estimates of the
number of people, sequencing machines, and dollars re-
quired to do the job. One of the skeptics pacing at the
edge of the room was Jim Watson, who 3 years later
became the first director of the U.S. component of the
genome project.
Much of the opposition to the HGP was defused by
two facts. First, in most countries, the HGP was
launched with an infusion of new money for science,
eliminating the argument that it took resources from
hypothesis-driven research. Second, scientists realized
the importance of sequencing bacteria, yeast, the nem-
atode, and the fruit fly as a preliminary to the human
genome. This had the effect of stimulating science across
a broad spectrum of biology and allowed many new
players to enter the mainstream of genome science.
I would like to emphasize the international character
of the HGP, because there is a tendency in this country
to think of the U.S. component as “The Genome Pro-
ject.” Certainly the United States has been and continues
to be a major driving force, and, in the early years, the
dozen or so genome centers geared to producing chro-
mosome-by-chromosome physical maps produced
many of the cosmids, YACS, and BACS that became
the substrate for the public sequencing project. But it
was scientists at Ge´ne´thon in France who demonstrated
that YAC maps could be constructed for the whole ge-
nome, instead of the more time-consuming chromo-
some-by-chromosome approach (Cohen et al. 1993).
They also added hundreds of polymorphic markers to
the genetic map, thereby anchoring the genetic map on
the growing physical map (Weissenbach et al. 1992).
One has to give enormous credit to Daniel Cohen and
Jean Weissenbach for these pioneering efforts.
In Britain, the Medical Research Council and theWell-
come Trust created the Sanger Center just outside Cam-
bridge. With Washington University in St. Louis, they
sequenced the genome ofCaenorhabditis elegans, the first
multicellular organism to be sequenced, and their con-
certed approach was a quantum leap ahead of the “cot-
tage industry” that had developed earlier to sequence the
yeast, Saccharomyces cerevisceae. I give full credit to John
Sulston and BobWaterston for this pioneering effort that
set the stage for the human genome–sequencing effort.
In fact, as these two groups completed the C. elegans
genome in 1998, they were already shifting sequencing
teams onto the human genome, and other labs from the
United States, France, Germany, Japan, and even China
joined the effort. At that time, most predicted 5 years to
completion of the human sequence, bringing the project
to fruition in 2003.
This prediction did not take into account the impa-
tience and energy of Craig Venter, nor the resources of
Celera. The international “public project” had barely set-
tled in to its 5-year grind when Celera announced that
they had assembled the money, the machines, and the
people to do the job in less than a third of the time,
projecting completion before the end of 2000. To prove
their point, they joined forces with key scientists working
on the Drosophila sequence and, in the space of a few
months, finished the sequence and initiated a 2-week re-
treat to begin the process of identifying all the genes and
describing their functions (Adams et al. 2000).
The essential difference between the government-
funded “public project” and Celera’s “private project”
was that the former was built on the premise that the
human genome had to be divided into “bite-sized”
chunks, all mapped to specific chromosomes and ordered
along the chromosome before sequencing could begin.
Celera, on the other hand, sequenced random fragments
from the whole genome and let the computers do the
assembly into chromosomes, relying heavily, however, on
the data freely available from the “public project” to
provide the anchor points for proper assembly.
While the media have portrayed these as competing
efforts and have essentially declared Celera the winner,
I think it important to point out that this was not, by
any stretch, a competition played on a level playing
field. Since the public project put all its data into a public
database as soon as it was generated and Celera did
not, it was a very one-sided affair.
Perhaps this is the point at which to commend the
pioneers of the public project for making the sequence
publicly available. Not everyone in the project agreed
with this philosophy, and I suspect that it would not
have been possible without the insistence of the leaders,
including Sulston and Waterston, Francis Collins on be-
half of the NIH, and Michael Morgan on behalf of the
Wellcome Trust.
Whatever else one says about the “public” versus
“private” project, one has to admit that completing the
sequence 3 years ahead of schedule is a good thing. If
the Celera data are released to the public in the new
year, as they have suggested, it will add greatly to the
total information on the human genome. If the data are
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available only with a restrictive material transfer agree-
ment, they will be far less useful than the information
from the public project.
So here we are in the year 2000, a draft sequence
essentially in hand and the world waiting to begin the
exploitation phase. Huge questions loom before us, and
the prospect of predicting what will unfold in the next
decade, the next century, and the next millennium is
quite daunting.
Looking Ahead
The main difficulty in predicting the future is that pre-
dictions are based on linear projections of current
knowledge, current technologies, and current thinking.
But the most important aspects of the future are largely
dependent on knowledge that we don’t yet have, tech-
nologies that have not yet been invented, and concepts
that haven’t yet developed. For this reason I do not plan
to spend a lot of time on predicting the future. I am
confident that the future will be exciting, that it will
have a huge impact on the practice of medicine, and that
it will challenge us all in ways we have not yet thought
about. However, there are a few things we can say about
the near future, based on straight-line projections of cur-
rent knowledge.
For example, it would not be too big a stretch to sug-
gest that the greatest applications of genetics in the next
decade will involve molecular pharming—the use of ge-
netically modified plants and animals as vehicles for pro-
ducing valuable proteins. It is also quite clear that phar-
macogenomics is an area that will mature quickly and
that, within a few years, every useful polymorphism in
the genome will be identified and placed on a gene chip.
A genome screen will identify for each person what will
be the most efficacious drug with the fewest side effects,
and medicine will become tailored to the individual
rather than the population. I would also suggest that, in
human biology, the golden age of DNA is drawing to a
close. DNA will have given us the all-important cata-
logue, but the next big steps in understanding human
biology belong to the chemists, biochemists, cell biolo-
gists, and physiologists. Proteomics will take over from
genomics at the forefront of research in human biology.
Over the next quarter century, human genetics will
continue to have a role in defining disease genes. The
easy part, identifying genes for single-gene disorders, is
essentially over. Sorting out the genes that are involved
in the common complex diseases is altogether a different
matter and will take considerable time to realize because
of the complexity of gene-environment interaction. In
time, however, we will develop a detailed catalogue of
which genes contribute to which diseases, and to what
degree. How valuable this information will be for the
average person remains to be seen. And to what extent
individuals will alter their behavior on the basis of a
gene screen is a matter for considerable debate.
One area where I predict intense public interest is in
selection of children. Pre-implantation diagnosis for sin-
gle-gene diseases is now feasible, involving in vitro fer-
tilization with removal of a single cell from the eight-
cell embryo, for genetic testing. With new gene-chip
technologies, one can imagine that it will be possible to
examine each embryo for several hundred genetic char-
acteristics. This would allow parents to select children
with a particular combination of genetic assets and risks
while rejecting others with fewer assets or greater risks.
Since people are generally more concerned about the
attributes of their children than they are about them-
selves, it is not unreasonable to suggest that couples
with the necessary knowledge and resources will seek
to optimize their chances for having children with su-
perior attributes.
When we do get to the point where we understand
many of the genes involved in complex disorders, using
the information properly will require an enormous
amount of public education. And the public has a huge
appetite for it. Hardly a day goes by without a news
item about a gene for something or other—heart dis-
ease, baldness, bad behavior, good behavior, sexual
preference, weight control, and even aging. Yet my ex-
perience is that very often the articles themselves are
filled with misconceptions, and the expectations are to-
tally unrealistic. Often the headline itself is totally mis-
leading. And some are both misleading and astonishing.
One wonders sometimes whether the problem lies in the
quality of the information provided to the media or in
the capacity of the media to adequately interpret the
information. But one thing is certain, and that is the
need for all of us to be more involved in providing
accurate information and to be more ready to assist in
the interpretation of genetic information.
Role of the ASHG in the Public Dialogue
As President of the ASHG over the last 10 months, I
have been given the opportunity to deal with issues that
are at once sensitive, important, challenging, and dis-
turbing. In each case, the Society has either been called
upon to respond with a public statement, to endorse
someone else’s statement, or to provide input to a gov-
ernment document. The issues have been varied, and
many of them have been far removed from my area of
expertise. As a Canadian, I have found it a special chal-
lenge to deal with a system of government that is foreign
to me, and I have therefore relied heavily on my Board
colleagues, especially the past and future Presidents.
I want to illustrate the ASHG public dialogue with
three examples. The first, and by far themost significant,
was the death of Jesse Gelsinger, the 18-year-old Ari-
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zona man who lost his life in a gene-therapy experiment
in September 1999. This sent shock waves throughout
the scientific community and raised new questions about
the prospects for gene therapy. The astonishment to our
community was that the experimental therapy was be-
ing carried out by a group led by Jim Wilson, then one
of the country’s most respected researchers, in a highly
respected academic program right here in Philadelphia.
The ramifications of this unexpected death were pro-
found. During the first few months of my presidency,
investigations by the FDA began to reveal a number of
problems with the trial, and calls began to grow for
more oversight of gene therapy. The scrutiny spread to
all gene-therapy trials and revealed that many investi-
gators and sponsors have either failed to report serious
adverse events to the RAC or have requested that such
reports be shielded from the public view. According to
an NIH audit of adenoviral protocols following Mr.
Gelsinger’s death, only 5% of observed serious adverse
events, including deaths, were ever reported to the NIH.
This raised a question for the Society—what, if any-
thing, should we be doing? The Society has a keen in-
terest in gene therapy, its scientific basis, and its trans-
lation into clinical practice. ASHG members are
frequently called upon to provide advice to families pre-
sented with the opportunity to participate in experi-
mental gene therapy. On this basis, the ASHG Board
considered it appropriate to develop a statement on gene
therapy. Our statement, published earlier this year,
makes several points. One is the need for more-rigorous
research, referring specifically to unrealistic expecta-
tions, attributed in some cases to overzealous pro-
nouncements by gene-therapy enthusiasts. Another was
that clinical trials should be undertaken only after solid
evidence of both safety and efficacy in appropriate an-
imal models. We argued that the greatest responsibility
for patient safety lies with the investigators themselves,
who more than anyone should know the potential risks
and benefits of the proposed trial. We concluded by
suggesting a “litmus test” for ASHG members faced
with advising families on participation in experimental
procedures: “… if you or your family were in this cir-
cumstance, would you enroll yourself or your loved one
in this trial?” We concluded that only in the case of an
affirmative answer to this question would it be appro-
priate to seek patients for enrollment or to support a
family’s decision to enter a clinical trial.
One of the areas in which we failed to take a strong
stand was on the issue of conflict of interest, for those
who are engaged in clinical trials and also have a fi-
nancial interest in the sponsoring company. Our posi-
tion was that as long as the conflict of interest is declared
and as long as institutional policies are followed, this
is sufficient. Others, however, have taken a stronger
stance. Rodney Howell, President of the American Col-
lege of Medical Geneticists, in an article published in a
Miami newspaper, unequivocally stated that such con-
flict of interest was unacceptable. Similarly, the Amer-
ican Society of Gene Therapy issued a public statement
with the same hard stance on such conflict. Partly as a
result of these strong statements, my own view is rapidly
changing. I have come to the conclusion that active
participation in a clinical trial, either as a referring phy-
sician, as a clinical researcher, or as part of the scientific
team, when one has a financial stake in the outcome,
is a conflict that should not be allowed under any cir-
cumstance. I wish now that we had put this into our
published statement.
The second important issue was the invitation to re-
spond to revised guidelines being considered by the U.S.
Patent and Trademark Office in relation to the patenting
of genes. In our March 22, 2000, response, we endorsed
some of the changes designed to “raise the bar” on cri-
teria needed to obtain a patent, and we went a step fur-
ther. Referring to our earlier 1991 published statement
on patenting, we argued that patentability should be
based on demonstrated function and utility, not on a
theoretical function derived from comparative sequence
analysis. Our message was consistent with theMarch 14,
2000, statement by President Clinton and British Prime
Minister Tony Blair, which stated that “to realize the full
promise of research, raw fundamental data on the human
genome, including the human DNA sequence and its var-
iations, should be made freely available to scientists eve-
rywhere.” This triggered the biggest-ever decline in the
value of biotechnology stocks.How their statement could
cause such precipitous reaction is beyond my compre-
hension, and it points to an astonishingly unsophisticated
knowledge base among biotech investors.
The third issue that we faced and that I want to share
with you is the halting of all human-subject research at
Virginia Commonwealth University (VCU) by the Fed-
eral Office for Protection from Research Risks. The case
that triggered this action involved the father of a re-
search participant, who complained to federal officials
about a VCU genetics study asking his daughter ques-
tions about her family history that he considered an
invasion of his own privacy. He argued strenuously that,
for his daughter to provide family information on a
questionnaire, the informed consent of every family
member for whom information was disclosed was re-
quired. On the face of it, this seems to be a logical stance
for him to take, although in practical terms it is not
hard to see how this could hamper genetics research.
This troubled genetics researchers because inquiring
about the family history from a third party has always
been an integral part of human genetics research. In-
deed, the procedure for collecting family history data
at VCU that was the subject of the original complaint
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has subsequently been rereviewed and approved by a
second independent institutional review board (IRB).
While the ASHG had no opportunity or reason to
intervene in this decision, we did think that it was im-
portant to inform the Society membership through a
“membership alert” prepared by our past president, Uta
Francke. The alert warned that, if all members of a family
had to be considered as research subjects, subject to in-
formed consent, then it would be “enormously cumber-
some and prohibitive, and will seriously impede medical
research.” Uta also conceded, however, that the father
has a point, and that it is incumbent upon genetics re-
searchers to consider seriously whether family members
about whom they collect family history should be cate-
gorized as human subjects, subject to informed consent.
The Public Trust
Following the alert, I had the opportunity to commu-
nicate in several e-mail exchanges with the man who
lodged the original complaint. His outrage was an eye-
opener for me, and it soon became clear that it was based
not only on his daughter’s disclosure of information that
he considered to be intensely personal, but also on his
perceptions of IRBs that failed to protect the public’s
interest. As he pointed out to me, one only has to read
the Washington Post to come away with a view that
research, especially in genetics, is out of control and
inconsistent with the value system of most Americans.
Whether or not this is a valid view is immaterial; it is
the perception of the truth as portrayed in the public
press that dictates public opinion. As I am not a regular
reader of the Washington Post, he offered to send me a
file with downloaded information from the their Web
site. Again, it was an eye-opener. Here are a few of the
headlines he encountered in his everyday reading.
GENE THERAPY RUN AMOK (January 29, 2000)
A LOT OF RULES, TOO MANY EXCEPTIONS
(January 30, 2000)
OUR FLIMSY SURVEILLANCE OF SCIENCE (Jan-
uary 31, 2000)
GENE TEST ERRORS WENT UNREPORTED (Feb-
ruary 11, 2000)
PROTECTION OF PATIENTS IN RESEARCH IS
FAULTED (April 13, 2000)
PATIENT’S DEATH IN GENE TEST NOT RE-
PORTED (May 3, 2000)
CAN SCIENCE BE SUPERVISED? (editorial, June 6,
2000)
Is it any wonder that he is enraged and ready to do
battle with a system that seems to have failed him, cer-
tainly failed Jesse Gelsinger, and apparently failed many
others? If the litany of charges contained in the articles
under these headlines are all true, then we have a very
large problem indeed. If only some of the charges are
true, it is still a huge problem, as the perception of
wrongdoing is a problem for all of us. I do not believe
for a moment, however, that the problem is only one
of perception.
What we do about it is the subject of my final few
moments.
The Future of the ASHG
Every ASHG President wants to be remembered for
something and to leave the Society in a little better shape
than he or she found it. On assuming my new title in
January of 2000, I was concerned about the role of the
Society and how well it performed in its chosen role.
Two things were clear—we have a very good Journal
that gets better each year, and we have a very good
annual meeting that most people in the Society attend
regularly. Both make money for the Society. Further-
more, we have a great office staff in Washington, we are
financially stable, and people like the membership di-
rectory. What more could we ask?
Consulting the last two Presidents, I heard from Uta
and Art that we are missing something. We serve our
members well, but we are not visible enough. We have
only a small “presence” inWashington, and no presence
whatsoever anywhere else in the United States. When
opportunities arise for input on important issues in
Washington (and, I might add, in Ottawa), we are not
always at the top of the list of organizations to be con-
sulted. The National Human Genome Research Insti-
tute, for example, seemed to have far more visibility
and influence than our Society, yet it is the Society that
represents the majority of researchers in human genetics
in North America.
But is this bad? Should we be presenting ourselves
more actively? Should we be proactive in addressing the
issues that are out in the public domain? To address
these questions, we decided in October 1999 that it was
time for a Board retreat—2 days away from our labs,
offices, and clinics, to review the Society, its strengths
and weaknesses, and its purpose. We enlisted the help
of Brook Rolter, as facilitator, and met for 2 days on
May 5 and 6, just prior to the annual spring Board
meeting on May 7, 2000. From all accounts, the time
invested was worthwhile, and I believe we have set the
Society on a new course.
In essence, we decided that the Society could not af-
ford to confine its main activities to the Journal and the
annual meeting. We decided that we needed to adopt a
mandate that includes lobbying, public education, and
advocacy. This is not new to the Society, and we have
for years had committees that dealt with education and
with social issues. We have also provided support for
congressional fellows who spend a year in Washington
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learning the inner workings of government. Despite
these measures, the Board’s concern was that the Society
itself worked in a largely reactive mode and that it
needed to become proactive. Furthemore, I was con-
cerned that the President is expected to function as the
“keeper of the light” for the Society, yet I already had
a full-time job and often felt like an absentee lighthouse
keeper—running to head off impending disaster at every
turn in the weather.
Given this, the Board took two very important de-
cisions at its retreat and formalized these decisions at
the Board meeting the following day. The first is to hire
a full-time professional geneticist as Executive Vice Pres-
ident (EVP) of the Society. This person will be a well-
respected geneticist who will have credibility with the
members of the Society, with government, and with the
public. The EVP will report to the Board through the
elected President and will not have any substantial ad-
ministrative duties, as these will still be the responsi-
bility of the Executive Director. We have already cir-
culated notice of this position via e-mail, and the
position will be advertised shortly in the Journal.
The second decision was to hire a part-time Web Ed-
itor to guide the further development of our Web site
and to make it a professional arm of the Society, much
like the Journal. The Board views the Web Editor as
being similar to the Journal Editor. The appointment
will be for an extended period of time and will be re-
munerated by the Society in proportion to the time com-
mitment. The Web Editor will work from his or her
academic home base and will be able to hire a full-time
Web Master to develop and maintain the site.
Although this will be costly, the Board is convinced
that we cannot afford not to make this important tran-
sition. We are entering into a period when genetics will
dominate the field of medicine and health care andwhen
the media will be filled with information about devel-
opments in genetics. As Senator Edward Kennedy once
said, “The public will immerse itself in the affairs of
science. Whether or not it does so constructively will
depend on the willingness of scientists to welcome pub-
lic participation.” The Board has, I believe, taken the
necessary steps to ensure that your Society will be at
this exciting forefront, able and willing to partake in
and occasionally lead the public discourse on the future
of molecular medicine.
Thank you, and enjoy the rest of the meeting.
References
Adams MD, Celniker SE, Holt RA, Evans CA, Gocayne JD,
Amanatides PG, Scherer SE, et al (2000) The genome se-
quence ofDrosophila melanogaster. Science 287:2185–2195
Botstein D, White RL, Skolnick M, Davis RW (1980) Con-
struction of a genetic linkage map in man using restriction
fragment length polymorphisms. Am J Hum Genet 32:
314–331
Cohen D, Chumakov I, Weissenbach J (1993) A first-genera-
tion physical map of the human genome. Nature 366:
698–701
Dunn LC (1962) Cross currents in the history of human ge-
netics. Am J Hum Genet 14:1–13
Hamerton J (1976) Human population cytogenetics: dilemmas
and problems. Am J Hum Genet 28:107–122
Kan YW, Golbus MS, Trecartin R (1976) Prenatal diagnosis
of sickle-cell anemia. N Engl J Med 294:1039–1040
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox
TK, Chakravarti A, Buchwald M, Tsui LC (1989) Identifi-
cation of the cystic fibrosis gene: genetic analysis. Science
245:1073–1080
McKusick V (1975) The growth and development of human
genetics as a clinical discipline. Am J Hum Genet 27:
261–273
Muller HJ (1950) Our load of mutations. Am J Hum Genet
2:111
Ray PN, Belfall B, Duff C, Logan C, Kean V, Thompson MW,
Sylvester JE, Gorski JL, Schmickel RD, Worton RG (1985)
Cloning of the breakpoint of an X;21 translocation asso-
ciated with Duchenne muscular dystrophy. Nature 318:
672–675
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R,
Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al
(1989) Identification of the cystic fibrosis gene: cloning and
characterization of complementary DNA. Science 245:
1066–1073 (erratum [1989], Science 245:1437)
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer
G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N,
et al (1989) Identification of the cystic fibrosis gene: chro-
mosome walking and jumping. Science 245:1059–1065
Verellen-Dumoulin C, FreundM, DeMeyer R, Laterre C, Fred-
eric J, Thompson MW, Markovic VD, Worton RG (1984)
Expression of an X-linked muscular dystrophy in a female
due to translocation involving Xp21 and non-random in-
activation of the normal X chromosome. Hum Genet 67:
115–119
Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Mil-
lasseau P, Vaysseix G, Lathrop M (1992) A second-gener-
ation linkage map of the human genome [see comments].
Nature 359:794–801
